PT  - JOURNAL ARTICLE
AU  - Alex Mu
AU  - Erica Weinberg
AU  - Dwight E. Moulin
AU  - Hance Clarke
TI  - Pharmacologic management of chronic neuropathic pain
DP  - 2017 Nov 01
TA  - Canadian Family Physician
PG  - 844--852
VI  - 63
IP  - 11
4099  - http://www.cfp.ca/content/63/11/844.short
4100  - http://www.cfp.ca/content/63/11/844.full
SO  - Can Fam Physician2017 Nov 01; 63
AB  - Objective To provide family physicians with a practical clinical summary of the Canadian Pain Society (CPS) revised consensus statement on the pharmacologic management of neuropathic pain.Quality of evidence A multidisciplinary interest group within the CPS conducted a systematic review of the literature on the current treatments of neuropathic pain in drafting the revised consensus statement.Main message Gabapentinoids, tricyclic antidepressants, and serotonin-norepinephrine reuptake inhibitors are the first-line agents for treating neuropathic pain. Tramadol and other opioids are recommended as second-line agents, while cannabinoids are newly recommended as third-line agents. Other anticonvulsants, methadone, tapentadol, topical lidocaine, and botulinum toxin are recommended as fourth-line agents.Conclusion Many pharmacologic analgesics exist for the treatment of neuropathic pain. Through evidence-based recommendations, the CPS revised consensus statement helps guide family physicians in the management of patients with neuropathic pain.